Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 5/20 | 0.58 |
| ▸ | RORC | P51449 | 9/20 | 0.56 |
| ▸ | KDM4A | O75164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18275317 | 0.88 | RORC (0.52) | ABL1RIN1RORC | |
| SCHEMBL18275325 | 0.87 | RORC (0.56) | RORCALDH1A1 | |
| SCHEMBL18275230 | 0.85 | RORC (0.53) | RORC | |
| SCHEMBL18294253 | 0.85 | RORC (0.56) | RORC | |
| SCHEMBL18275253 | 0.83 | RORC (0.59) | RORC | |
| SCHEMBL18275323 | 0.83 | RORC (0.62) | RORC | |
| SCHEMBL18294324 | 0.82 | RORC (0.57) | RORC | |
| SCHEMBL18275264 | 0.82 | RORC (0.52) | ABL1RIN1RORCALDH1A1 | |
| SCHEMBL18294272 | 0.81 | RORC (0.57) | RORC | |
| SCHEMBL18275330 | 0.81 | RORC (0.65) | ABL1RIN1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303291-B1 | ROR-GAMMA MODULATORS | LEAD PHARMA B V (NL) | 2020-03-18 | — | — | EP | claimed |
| US-10315996-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2019-06-11 | — | — | US | claimed |
| US-20180170877-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-21 | — | — | US | claimed |
| EP-3101006-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Cel Models IP B.V. (NL) | 2016-12-07 | — | — | EP | claimed |
| CN-108473429-B | ROR gamma modulators | 领先制药控股公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10315996-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2019-06-11 | — | — | US | disclosed |
| US-10315996-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2019-06-11 | — | — | US | disclosed |
| US-20180170877-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-21 | — | — | US | disclosed |
| US-20180170877-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-21 | — | — | US | disclosed |
| US-20180170877-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-21 | — | — | US | disclosed |
| WO-2016193452-A1 | ROR GAMMA (RORγ) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | disclosed |
| EP-3101006-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Cel Models IP B.V. (NL) | 2016-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315996-B2 | ROR gamma (RORγ) modulators | RORA, RORB, RORC | ABL1 2175/4885RIN1 1031/4885RORC 3/4885 |
| US-20180170877-A1 | ROR GAMMA (RORY) MODULATORS | RORA, RORB, RORC | ABL1 2035/4885RIN1 1084/4885RORC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.